5 Best ASX Stocks to Buy Now

2. CSL Limited (ASX:CSL.AX)

Market Capitalization as of 3/20 in Australian Dollars: 137.427 billion

CSL Limited (ASX:CSL.AX) is an Australian biotech company with global operations that focuses on serious and rare diseases. For the 6 months ended December 31, 2022, the company had net profit after tax of US$1.62 billion, steady on a constant currency basis. Underlying profit was up 10% year over year and revenue was up 25% year over year on a constant currency basis. For the period, CSL Limited (ASX:CSL.AX) experienced strong growth in immunoglobulin and albumin sales as well as record levels of plasma collections. If it keeps innovating successfully, CSL Limited (ASX:CSL.AX) could continue to grow.